Skip to main content

Illumina's Q4 Revenues Leap 163 Percent as Profits Soar

NEW YORK (GenomeWeb News) — Illumina today said fourth-quarter revenues jumped 163 percent as R&D spending rose 17 percent and profit soared.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $60.4 million from $23 million year over year.
 
R&D spending increased to $8.8 million from $7.5 million year over year.
 
The company said profit increased to $17.1 million from $326,000 in the year-ago period.
 
Illumina said it had around $130.7 million in cash, cash equivalents, and short-term investments as of Dec. 31.
 
The company said it expects 2007 revenue to be between $295 million and $315 million. First-quarter revenues are expected to be between $64 million and $68 million.
 
In the fourth quarter, Illumina completed the acquisition of Solexa for $600 million, and added two Solexa board members to its board.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.